Translational biology of osteosarcoma

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945

Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion

Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.

Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351

Immunogenic Cell Death in Cancer Therapy

Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303

WHO Classification of Tumours of Soft Tissue and Bone: WHO Classification of Tumours, vol. 5

Fletcher, C. D. �., Bridge, J., Hogendoorn, P. C. W., & Mertens, F. (2013) · Cited by 3,072

WHO classification of tumours of soft tissue and bone

Fletcher, C. D. �. (2013) · Cited by 2,874

Massive genomic rearrangement acquired in a single catastrophic event during cancer development

Stephens, P. J., Greenman, C. D., Fu, B., Yang, F., Bignell, G. R., Mudie, L. J., Pleasance, E. D., Lau, K. W., Beare, D., Stebbings, L. A., et al. (2011) · Cell · doi:10.1016/j.cell.2010.11.055 · Cited by 2,414

Immunological aspects of cancer chemotherapy

Zitvogel, L., Apetoh, L., Ghiringhelli, F., & Kroemer, G. (2008) · Nature Reviews Immunology · doi:10.1038/nri2216 · Cited by 1,712

RANK is essential for osteoclast and lymph node development.

Dougall, W. C., Glaccum, M., Charrier, K., Rohrbach, K., Brasel, K., De Smedt, T., Daro, E., Smith, J., Tometsko, M. E., Maliszewski, C. R., et al. (1999) · Genes & Development · doi:10.1101/gad.13.18.2412 · Cited by 1,478

RGS12 is a novel tumor suppressor in osteosarcoma that inhibits YAP-TEAD1-Ezrin signaling

Li, Y., Liu, M., Yang, S., Fuller, A. M., Eisinger‐Mathason, T. S. K., & Yang, S. (2021) · Oncogene · doi:10.1038/s41388-020-01599-z · Cited by 32

MALDI-TOF Mass Spectrometry Profiling of Plasma Exosomes Evaluates Osteosarcoma Metastasis

Han, Z., Peng, C., Yi, J., Wang, Y., Liu, Q., Yang, Y., Long, S., Qiao, L., & Shen, Y. (2021) · iScience · doi:10.1016/j.isci.2021.102906 · Cited by 32

Trends in Tumor Site-Specific Survival of Bone Sarcomas from 1980 to 2018: A Surveillance, Epidemiology and End Results-Based Study

Hu, X., Deng, K., Ye, H., Sun, Z., Huang, W., Sun, Y., & Yan, W. (2021) · Cancers · doi:10.3390/cancers13215381 · Cited by 34

IGF2BP1-regulated expression of ERRα is involved in metabolic reprogramming of chemotherapy resistant osteosarcoma cells

He, Q., Peng, H. F., He, G., Mai, H., Liu, W., Zhang, W., Zhang, K., Zhong, G., Guo, R., Yu, C., et al. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03549-7 · Cited by 32

Sono-activable and biocatalytic 3D-printed scaffolds for intelligently sequential therapies in osteosarcoma eradication and defect regeneration

Rong, X., Xiao, S., Geng, W., Zhu, B., Mou, P., Ding, Z., Zhang, B., Fan, Y., Qiu, L., & Cheng, C. (2025) · Nature Communications · doi:10.1038/s41467-025-61377-x · Cited by 32

Molecular Pathology of Bone Tumors

Lam, S. W., van IJzendoorn, D. G. P., Cleton-Jansen, A., Szuhai, K., & Bovée, J. V. M. G. (2018) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2018.11.002 · Cited by 32

Aurora B kinase as a novel molecular target for inhibition the growth of osteosarcoma

Zhao, Z., Jin, G., Yao, K., Liu, K., Liu, F., Chen, H., Wang, K., Gorja, D. R., Reddy, K., Bode, A. M., et al. (2019) · Molecular Carcinogenesis · doi:10.1002/mc.22993 · Cited by 31

Autophagy in Osteosarcoma Cancer Stem Cells Is Critical Process which Can Be Targeted by the Antipsychotic Drug Thioridazine

Camuzard, O., Trojani, M.-C., Santucci‐Darmanin, S., Pagnotta, S., Breuil, V., Carle, G. F., & Pierrefite‐Carle, V. (2020) · Cancers · doi:10.3390/cancers12123675 · Cited by 32

Novel insights into the METTL3-METTL14 complex in musculoskeletal diseases

Xu, Y., Zhang, Y., Luo, Y., Qiu, G., Lu, J., He, M., & Wang, Y. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01435-9 · Cited by 31

FePSe3‐Nanosheets‐Integrated Cryogenic‐3D‐Printed Multifunctional Calcium Phosphate Scaffolds for Synergistic Therapy of Osteosarcoma

Xu, C., Xia, Y., Zhuang, P., Liu, W., Mu, C., Liu, Z., Wang, J., Chen, L., Dai, H., & Luo, Z. (2023) · Small · doi:10.1002/smll.202303636 · Cited by 31

Combination of etoposide and fisetin results in anti-cancer efficiency against osteosarcoma cell models

de Oliveira, J. M. P. F., Pacheco, A. R., Coutinho, L., Oliveira, H., Pinho, S., Almeida, L., Fernandes, E. G. R., & Santos, C. (2017) · Archives of Toxicology · doi:10.1007/s00204-017-2146-z · Cited by 31

Nanomedicine in osteosarcoma therapy: Micelleplexes for delivery of nucleic acids and drugs toward osteosarcoma-targeted therapies

Pereira‐Silva, M., Alvarez‐Lorenzo, C., Concheiro, Á., Paiva‐Santos, A. C., Veiga, F., & Figueiras, A. (2020) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2019.10.013 · Cited by 32

WNT5B drives osteosarcoma stemness, chemoresistance and metastasis

Perkins, R. S., Murray, G., Suthon, S., Davis, L., Perkins, N. B., Fletcher, L. B., Bozzi, A., Schreiber, S. L., Lin, J., Laxton, S. J., et al. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1670 · Cited by 30

SLC38A5 suppresses ferroptosis through glutamine-mediated activation of the PI3K/AKT/mTOR signaling in osteosarcoma

Huang, X., Xia, K., Wei, Z., Liu, W., Wei, Z., & Guo, W. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05803-6 · Cited by 31

The Emerging Role of Exosomal Non-coding RNAs in Musculoskeletal Diseases

Tu, C., He, J., Chen, R., & Li, Z. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666191113104946 · Cited by 30

miR-1225-5p Functions as a Tumor Suppressor in Osteosarcoma by Targeting Sox9

Zhang, W., Wei, L., Sheng, W., Kang, B., Wang, D., & Zeng, H. (2019) · DNA and Cell Biology · doi:10.1089/dna.2019.5105 · Cited by 30

MicroRNA-509-3p inhibits cellular migration, invasion, and proliferation, and sensitizes osteosarcoma to cisplatin

Patil, S. L., Palat, A., Pan, Y., Rajapakshe, K., Mirchandani, R., Bondesson, M., Yustein, J. T., Coarfa, C., & Gunaratne, P. H. (2019) · Scientific Reports · doi:10.1038/s41598-019-55170-2 · Cited by 30

Pazopanib and Trametinib as a Synergistic Strategy against Osteosarcoma: Preclinical Activity and Molecular Insights

Chiabotto, G., Grignani, G., Todorovic, M., Martín, V., Centomo, M. L., Prola, E., Giordano, G. D., Merlini, A., Miglio, U., Berrino, E., et al. (2020) · Cancers · doi:10.3390/cancers12061519 · Cited by 30

Role of TKI for Metastatic Osteogenic Sarcoma

Duffaud, F. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00760-w · Cited by 30

Metal-drug nanoparticles-mediated osteolytic microenvironment regulation for enhanced radiotherapy of orthotopic osteosarcoma

Geng, H., Zhou, M., Li, B., Liu, L., Yang, X., Wen, Y., Yu, H., Wang, H., Chen, J., & Chen, L. (2020) · Chemical Engineering Journal · doi:10.1016/j.cej.2020.128103 · Cited by 30

Natural Polyphyllins (I, II, D, VI, VII) Reverses Cancer Through Apoptosis, Autophagy, Mitophagy, Inflammation, and Necroptosis

Ahmad, B., Gamallat, Y., Khan, M. F., Din, S. R. U., Israr, M., Ahmad, M., Tahir, N., Azam, N., Rahman, K. U., Wang, X., et al. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s287354 · Cited by 30

Improved osteosarcoma survival with addition of mifamurtide to conventional chemotherapy – Observational prospective single institution analysis

Múdrý, P., Kýr, M., Rohleder, O., Mahdal, M., Zambo, I. S., Ježová, M., Tomáš, T., & Štěrba, J. (2021) · Journal of bone oncology · doi:10.1016/j.jbo.2021.100362 · Cited by 30

Role of extracellular vesicles in osteosarcoma

Yang, Q., Liu, J., Wu, B., Wang, X., Jiang, Y., & Zhu, D. (2022) · International Journal of Medical Sciences · doi:10.7150/ijms.74137 · Cited by 31

The molecular landscape of extraskeletal osteosarcoma: A clinicopathological and molecular biomarker study

Jour, G., Wang, L., Middha, S., Zehir, A., Chen, W., Sadowska, J., Healey, J. H., Agaram, N. P., Choi, L. E., Nafa, K., et al. (2015) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.29 · Cited by 30

TIMP3 regulates osteosarcoma cell migration, invasion, and chemotherapeutic resistances

Han, X., Li, Y., Mo, H., Li, K., Lin, D., Zhao, C., Zhao, J., & Tang, T. (2016) · Tumor Biology · doi:10.1007/s13277-015-4757-4 · Cited by 30

Oestrogen‐related receptor alpha mediates chemotherapy resistance of osteosarcoma cells via regulation of ABCB 1

Chen, Y., Zhang, K.-S., Li, Y., Guo, R., Zhang, K., Zhong, G., & He, Q. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14123 · Cited by 30

Identification of DNA-PKcs as a primary resistance factor of salinomycin in osteosarcoma cells

Zhen, Y.-F., Li, S., Zhu, Y.-R., Wang, X., Zhou, X., & Zhu, L. (2016) · Oncotarget · doi:10.18632/oncotarget.12712 · Cited by 29

MiR-367 negatively regulates apoptosis induced by adriamycin in osteosarcoma cells by targeting KLF4

Wang, G.-C., He, Q., Tong, D., Wang, C., Liu, K., Ding, C., Ji, F., & Zhang, H. (2016) · Journal of bone oncology · doi:10.1016/j.jbo.2016.02.002 · Cited by 29

Hsa-miR-889-3p promotes the proliferation of osteosarcoma through inhibiting myeloid cell nuclear differentiation antigen expression

Ge, D., Chen, H., Zheng, S., Zhang, B., Ge, Y., Yang, L., & Cao, X. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108819 · Cited by 29

State-of-the-art, approved therapeutics for the pharmacological management of osteosarcoma

Meazza, C., & Asaftei, S. D. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1936499 · Cited by 29

Long Noncoding RNA GAS5: A New Factor Involved in Bone Diseases

Zhou, Z., Chen, J., Huang, Y., Liu, D., Chen, S., & Qin, S. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.807419 · Cited by 29

AMTB, a TRPM8 antagonist, suppresses growth and metastasis of osteosarcoma through repressing the TGFβ signaling pathway

Liu, Y., Leng, A., Li, L., Yang, B. H., Shen, S., Chen, H., Zhu, E., Xu, Q., Ma, X., Shi, P., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04744-6 · Cited by 29

Super-enhancer-driven MLX mediates redox balance maintenance via SLC7A11 in osteosarcoma

Guo, W., Wang, X., Lu, B., Yu, J., Xu, M., Huang, R., Cheng, M., Yang, M., Zhao, W., & Zou, C. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05966-y · Cited by 29

Astaxanthin as a Potent Antioxidant for Promoting Bone Health: An Up-to-Date Review

Davan, I., Fakurazi, S., Alias, E., Ibrahim, N. ‘., Ng, M. H., & Hassan, H. (2023) · Antioxidants · doi:10.3390/antiox12071480 · Cited by 30

Efficacy of glycogen synthase kinase-3β targeting against osteosarcoma via activation of β-catenin

Shimozaki, S., Yamamoto, N., Domoto, T., Nishida, H., Hayashi, K., Kimura, H. J., Takeuchi, A., Miwa, S., Igarashi, K., Kato, T., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12781 · Cited by 30

Amentoflavone Inhibits Metastatic Potential Τhrough Suppression of ERK/NF-ĸB Activation in Osteosarcoma U2OS Cells

Pan, P., Tsai, J., & Liu, Y. (2017) · Anticancer Research · doi:10.21873/anticanres.11900 · Cited by 29

Single-Cell Profiling of Tumor Microenvironment Heterogeneity in Osteosarcoma Identifies a Highly Invasive Subcluster for Predicting Prognosis

Guo, J., Tang, H., Huang, P., Guo, J., Shi, Y., Yuan, C., Liang, T., & Tang, K. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.732862 · Cited by 28

The fusion gene LRP1–SNRNP25 drives invasion and migration by activating the pJNK/37LRP/MMP2 signaling pathway in osteosarcoma

Xing, P., Liu, H., Xiao, W., Zhang, G., Zhang, C., Liao, Z., Li, T., & Yang, J. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-01962-z · Cited by 28

Endowing Pt(IV) with Perfluorocarbon Chains and Human Serum Albumin Encapsulation for Highly Effective Antitumor Chemoimmunotherapy

Xie, P., Jin, Q., Zhang, L., Zhang, H., Montesdeoca, N., Karges, J., Xiao, H., Mao, X., Song, H., & Shang, K. (2024) · ACS Nano · doi:10.1021/acsnano.4c01352 · Cited by 28

PAXX is a novel target to overcome resistance to doxorubicin and cisplatin in osteosarcoma

Ma, W., Yang, L., Liu, H., Chen, P., Ren, H., & Ren, P. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.10.108 · Cited by 28

What is the best clinical approach to recurrent/refractory osteosarcoma?

Meazza, C., Bastoni, S., & Scanagatta, P. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1760848 · Cited by 28

Preclinical Testing of a Novel Niclosamide Stearate Prodrug Therapeutic (NSPT) Shows Efficacy Against Osteosarcoma

Reddy, G. B., Kerr, D. L., Spasojević, I., Tovmasyan, A. G., Hsu, D. S., Brigman, B. E., Somarelli, J. A., Needham, D., & Eward, W. C. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0689 · Cited by 29

Circular RNA hsa_circ_0001649 suppresses the growth of osteosarcoma cells via sponging multiple miRNAs

Sun, D., & Zhu, D. (2020) · Cell Cycle · doi:10.1080/15384101.2020.1814026 · Cited by 28

A system-level approach identifies HIF-2α as a critical regulator of chondrosarcoma progression

Kim, H., Cho, Y., Kim, H. S., Kang, D., Cheon, D., Kim, Y., Chang, M. J., Lee, K. M., Chang, C. B., Kang, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18817-7 · Cited by 31

Role of the calcium-sensing receptor (CaSR) in cancer metastasis to bone: Identifying a potential therapeutic target

Tuffour, A., Kosiba, A. A., Zhang, Y., Addai, F. P., Gu, J., & Shi, H. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188528 · Cited by 28

Targeted Delivery of PD‐L1‐Derived Phosphorylation‐Mimicking Peptides by Engineered Biomimetic Nanovesicles to Enhance Osteosarcoma Treatment

Wu, W., Guo, H., Jing, D., Zhang, Z., Zhang, Z., Pu, F., Yang, W., Jin, X., Huang, X., & Shao, Z. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202200955 · Cited by 28

Complementary and Synergistic Design of Bi‐Layered Double Hydroxides Modified Magnesium Alloy toward Multifunctional Orthopedic Implants

Zhang, D., Li, M., Xu, R., Xie, J., Zhang, Y., Shi, Q., Qiao, Y., Peng, F., & Liu, X. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202201367 · Cited by 28

Multifunctional 3D-printed bioceramic scaffolds: Recent strategies for osteosarcoma treatment

Liu, X., Liu, Y., Qiang, L., Ya, R., Lin, Y., Li, H., Chen, Q., Gao, S., Yang, X., Zhang, C., et al. (2023) · Journal of Tissue Engineering · doi:10.1177/20417314231170371 · Cited by 30

Apurinic/apyrimidinic endonuclease 1 regulates angiogenesis in a transforming growth factor β‐dependent manner in human osteosarcoma

Jiang, X., Shan, J., Dai, N., Zhong, Z., Qing, Y., Yang, Y., Zhang, S., Li, C., Sui, J.-D., Ren, T., et al. (2015) · Cancer Science · doi:10.1111/cas.12763 · Cited by 28

UHRF1 promotes human osteosarcoma cell invasion by downregulating the expression of E-cadherin in an Rb1-dependent manner

Liu, W., QIAO, R. H., WANG, D. M., Huang, X. W., Li, B., & Wang, D. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.4515 · Cited by 28

Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models

Jian, C., Tu, M., Ho, P. Y., Duan, Z., Zhang, Q., Qiu, J.-X., White, R. D., Wun, T., Lara, P. N., Lam, K. S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16372 · Cited by 28

An Insight into the Roles of MicroRNAs and Exosomes in Sarcoma

Kohama, I., Kosaka, N., Chikuda, H., & Ochiya, T. (2019) · Cancers · doi:10.3390/cancers11030428 · Cited by 28

Antitumor activity of Raddeanin A is mediated by Jun amino‐terminal kinase activation and signal transducer and activator of transcription 3 inhibition in human osteosarcoma

Wang, Z., Shen, J., Sun, W. Y., Zhang, T., Zuo, D., Wang, H., Wang, G., Xu, J., Yin, F., Mao, M., et al. (2019) · Cancer Science · doi:10.1111/cas.14008 · Cited by 28

Prognostic value of patient‐derived xenograft engraftment in pediatric sarcomas

Castillo‐Ecija, H., Pascual‐Pasto, G., Pérez‐Jaume, S., Resa‐Pares, C., Vilà-Ubach, M., Monterrubio, C., Jimenez‐Cabaco, A., Baulenas‐Farres, M., Muñoz‐Aznar, O., Salvador, N., et al. (2021) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.210 · Cited by 27

MT2A is an early predictive biomarker of response to chemotherapy and a potential therapeutic target in osteosarcoma

Mangelinck, A., Costa, M. E. M. D., Stefanovska, B., Bawa, O., Polrot, M., Gaspar, N., & Fromigué, O. (2019) · Scientific Reports · doi:10.1038/s41598-019-48846-2 · Cited by 27

Selenium-doped calcium carbonate nanoparticles loaded with cisplatin enhance efficiency and reduce side effects

Zhao, P., Li, M., Chen, Y., He, C., Zhang, X., Fan, T., Yang, T., Lu, Y., Lee, R. J., Ma, X., et al. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118638 · Cited by 27

Circular RNA circNRIP1 plays oncogenic roles in the progression of osteosarcoma

Meng, Y., Hao, D., Huang, Y., Jia, S., Zhang, J., He, X., Liu, D., & Sun, L. D. (2021) · Mammalian Genome · doi:10.1007/s00335-021-09891-3 · Cited by 27

A Novel Six Metastasis-Related Prognostic Gene Signature for Patients With Osteosarcoma

Zheng, D., Xia, K., Yu, L., Gong, C., Shi, Y., Li, W., Qiu, Y., Yang, J. M., & Guo, W. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.699212 · Cited by 27

Osteosarcoma-targeted Cu and Ce based oxide nanoplatform for NIR II fluorescence/magnetic resonance dual-mode imaging and ros cascade amplification along with immunotherapy

Cheng, M., Kong, Q., Tian, Q., Cai, W., Wang, C., Yuan, M., Wang, W., Wang, P., & Yan, W. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02400-z · Cited by 26

NIR‐II AIEgens nanosystem for fluorescence and chemiluminescence synergistic imaging‐guided precise resection in osteosarcoma surgery

Li, R., Liu, K., Hu, Q., Shen, J., Zuo, D., Wang, H., Zhu, X., & Sun, W. (2024) · Aggregate · doi:10.1002/agt2.658 · Cited by 26

A Bayesian active learning platform for scalable combination drug screens

Tosh, C., Tec, M., White, J. B., Quinn, J. F., Sanchez, G. I., Calder, P., Kung, A. L., Cruz, F. S. D., & Tansey, W. (2025) · Nature Communications · doi:10.1038/s41467-024-55287-7 · Cited by 31

Downregulation of DEPTOR inhibits the proliferation, migration, and survival of osteosarcoma through PI3K/Akt/mTOR pathway

Hu, B., Lv, X., Gao, F., Chen, S., Wang, S., Qing, X., Liu, J., Wang, B., & Shao, Z. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s143518 · Cited by 26

NKX2-2 Suppresses Osteosarcoma Metastasis and Proliferation by Downregulating Multiple Target Genes

Chen, H.-M., Liu, W., Zhong, L., Liao, D., Zhang, R., Kang, T., & Wu, Y. (2018) · Journal of Cancer · doi:10.7150/jca.26382 · Cited by 26

Genetic aberrations and molecular biology of cardiac sarcoma

Urbini, M., Astolfi, A., Indio, V., Nannini, M., Pizzi, C., Paolisso, P., Tarantino, G., Pantaleo, M. A., & Saponara, M. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920918492 · Cited by 26

Blocking circ-CNST suppresses malignant behaviors of osteosarcoma cells and inhibits glycolysis through circ-CNST-miR-578-LDHA/PDK1 ceRNA networks

Hu, R., Chen, S., & Yan, J. (2021) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-021-02427-0 · Cited by 26

Comprehensive Analysis of a Zinc Finger Protein Gene–Based Signature with Regard to Prognosis and Tumor Immune Microenvironment in Osteosarcoma

Sun, X., Zheng, D., & Guo, W. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.835014 · Cited by 26

CDK7/GRP78 signaling axis contributes to tumor growth and metastasis in osteosarcoma

Zhang, T., Li, J., Yang, M., Ma, X., Wang, Z., Ma, X., Sun, M., Sun, W., Xu, J., Hua, Y., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02446-z · Cited by 26

In vivo and In vitro properties evaluation of curcumin loaded MgO doped 3D printed TCP scaffolds

Bhattacharjee, A., Jo, Y., & Bose, S. (2023) · Journal of Materials Chemistry B · doi:10.1039/d2tb02547g · Cited by 26

TRIM26 inhibited osteosarcoma progression through destabilizing RACK1 and thus inactivation of MEK/ERK signaling

Xia, K., Zheng, D., Wei, Z., Liu, W., & Guo, W. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06048-9 · Cited by 26

Up-regulation of HDAC9 promotes cell proliferation through suppressing p53 transcription in osteosarcoma.

Zhao, Y., Wang, Y., Cai, Q., Wang, J., & Yao, W. (2015) · PubMed Central · Cited by 26

Exploring targeted therapy of osteosarcoma using proteomics data

Chaiyawat, P., Settakorn, J., Sangsin, A., Teeyakasem, P., Klangjorhor, J., Soongkhaw, A., & Pruksakorn, D. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s119993 · Cited by 26

BMPR2 and HIF1-α overexpression in resected osteosarcoma correlates with distant metastasis and patient survival

Wang, S., Ren, T., Huang, Y., Bao, X., Sun, K., Shen, D., & Guo, W. (2017) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2017.05.09 · Cited by 26

Blood and tissue biomarker analysis in dogs with osteosarcoma treated with palliative radiation and intra-tumoral autologous natural killer cell transfer

Judge, S. J., Yanagisawa, M., Sturgill, I. R., Bateni, S. B., Gingrich, A. A., Foltz, J. A., Lee, D. A., Modiano, J. F., Monjazeb, A. M., Culp, W. T. N., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0224775 · Cited by 27

Ginsenoside Rg3 Inhibits the Growth of Osteosarcoma and Attenuates Metastasis through the Wnt/β‐Catenin and EMT Signaling Pathway

Mao, X., Jin, Y., Feng, T., Wang, H., Liu, D., Zhou, Z., Yan, Q., Yang, H., Yang, J.-R., Yang, J. F., et al. (2020) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2020/6065124 · Cited by 26

Gene Expression Classifier Reveals Prognostic Osteosarcoma Microenvironment Molecular Subtypes

Song, Y., Xu, Y., Deng, C., Zhu, X., Fu, J., Chen, H., Lu, J., Xu, H., Song, G., Tang, Q., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.623762 · Cited by 26

Ubiquitin-conjugating enzyme E2S (UBE2S) as a prognostic biomarker and regulator of tumorigenesis in osteosarcoma

Liu, B., Li, C., He, S., Li, Z., Wang, H., Feng, C., Xiong, Z., Tu, C., Song, D., & Li, Z. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114545 · Cited by 25

Targeted Chemotherapy in Bone and Soft-Tissue Sarcoma

Harwood, J. L., Alexander, J. H., Mayerson, J. L., & Scharschmidt, T. J. (2015) · Orthopedic Clinics of North America · doi:10.1016/j.ocl.2015.06.011 · Cited by 25

LncRNA SNHG15 contributes to doxorubicin resistance of osteosarcoma cells through targeting the miR-381-3p/GFRA1 axis

Zhang, J., Rao, D., Ma, H., Kong, D., Xu, X., & Lu, H. (2020) · Open Life Sciences · doi:10.1515/biol-2020-0086 · Cited by 25

Drug delivery nanocarriers and recent advances ventured to improve therapeutic efficacy against osteosarcoma: an overview

Desai, S. A., Manjappa, A. S., & Khulbe, P. (2021) · Journal of the Egyptian National Cancer Institute · doi:10.1186/s43046-021-00059-3 · Cited by 25

Frequently expressed glypican‐3 as a promising novel therapeutic target for osteosarcomas

Nie, J., Yang, T., Li, H., Li, S., Li, T., Ye, H., Lu, M., Chu, X., Zhong, G., Zhou, J., et al. (2022) · Cancer Science · doi:10.1111/cas.15521 · Cited by 25

Integration of single-cell RNA sequencing and bulk RNA sequencing to reveal an immunogenic cell death-related 5-gene panel as a prognostic model for osteosarcoma

Yang, J., Zhang, J., Na, S., Wang, Z., Li, H., Su, Y., Ji, L., Tang, X., Yang, J., & Lu, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.994034 · Cited by 25

The interaction between osteosarcoma and other cells in the bone microenvironment: From mechanism to clinical applications

Zeng, J., Peng, Y., Wang, D., Ayesha, K., & Chen, S. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1123065 · Cited by 31

Advanced nanoparticles, the hallmark of targeted drug delivery for osteosarcoma-an updated review

Ashique, S., Faiyazuddin, M., Afzal, O., Gowri, S., Hussain, A., Mishra, N., Garg, A., Maqsood, S., Akhtar, M. S., & Altamimi, A. S. A. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104753 · Cited by 27

DNA strand breaks induced by nuclear hijacking of neuronal NOS as an anti-cancer effect of 2-methoxyestradiol

Górska‐Ponikowska, M., Kuban‐Jankowska, A., Zmijewski, M. A., Marino, A., Cappello, F., Wnuk, M., Gorzynik-Debicka, M., Rzeszutek, I., Daca, A., Lewińska, A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3913 · Cited by 25

Target-activated transcription for the amplified sensing of protease biomarkers

Liu, F., Yang, M., Song, W., Luo, X., Tang, R., Duan, Z., Kang, W., Xie, S., Liu, Q., Lei, C., et al. (2020) · Chemical Science · doi:10.1039/c9sc04692e · Cited by 25

Locally Controlled Release of Methotrexate and Alendronate by Thermo-Sensitive Hydrogels for Synergistic Inhibition of Osteosarcoma Progression

Shan, H., Li, K., Zhao, D., Chi, C., Tan, Q., Wang, X., Yu, J., & Piao, M. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00573 · Cited by 25

ELK1-induced upregulation lncRNA LINC02381 accelerates the osteosarcoma tumorigenesis through targeting CDCA4 via sponging miR-503–5p

Bian, X., Sun, Y., Wang, L., & Shang, Y.-L. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.02.072 · Cited by 25

LncRNA LOC100129620 promotes osteosarcoma progression through regulating CDK6 expression, tumor angiogenesis, and macrophage polarization

Chen, Y., Tang, G., Qian, H., Chen, J., Cheng, B., Zhou, C., & Shen, Y. (2021) · Aging · doi:10.18632/aging.203042 · Cited by 25

Natural Chlorogenic Acid Planted Nanohybrids with Steerable Hyperthermia for Osteosarcoma Suppression and Bone Regeneration

Yang, Y., Zheng, Y., Liu, J., Chang, Z., Wang, Y., Shao, Y., Hou, R., & Zhang, X. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202300325 · Cited by 24

Carboxypeptidase E-ΔN promotes migration, invasiveness, and epithelial–mesenchymal transition of human osteosarcoma cells via the Wnt–β-catenin pathway

Fan, S., Gao, X., Chen, P., & Li, X. (2018) · Biochemistry and Cell Biology · doi:10.1139/bcb-2018-0236 · Cited by 24

Biomimetic triphase composite scaffolds with antibacterial and anti-tumor potentials for bone repair

Li, K., Cai, K., Ran, Q., & Jiang, D. (2019) · Materials Letters · doi:10.1016/j.matlet.2019.126590 · Cited by 24

Runx3 is required for oncogenic Myc upregulation in p53-deficient osteosarcoma

Otani, S., Date, Y., Ueno, T., Ito, T., Kajikawa, S., Omori, K., Taniuchi, I., Umeda, M., Komori, T., Toguchida, J., et al. (2021) · Oncogene · doi:10.1038/s41388-021-02120-w · Cited by 25

Identification of mitochondrial RNA polymerase as a potential therapeutic target of osteosarcoma

Han, Q., Zhang, X.-Y., Yan, P., Chen, S., Liu, F., Zhu, Y.-R., & Tian, Q. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00780-x · Cited by 24

Tumor Customized 2D Supramolecular Nanodiscs for Ultralong Tumor Retention and Precise Photothermal Therapy of Highly Heterogeneous Cancers

Peng, L., Xue, Y., Mu, X., Shao, Y., Lu, Q., Jin, X., Yinwang, E., Zhang, Z., Zhou, H., Teng, W., et al. (2022) · Small · doi:10.1002/smll.202200179 · Cited by 24

ANGPTL4 negatively regulates the progression of osteosarcoma by remodeling branched-chain amino acid metabolism

Lin, S., Miao, Y., Zheng, X., Dong, Y., Yang, Q., Yang, Q., Du, S., Xu, J., Zhou, S., & Yuan, T. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01029-x · Cited by 24

The perplexing role of immuno-oncology drugs in osteosarcoma

Smrke, A., Tam, Y. B., Anderson, P. M., Jones, R. L., & Huang, P. H. (2021) · Journal of bone oncology · doi:10.1016/j.jbo.2021.100400 · Cited by 9

Future directions in the treatment of osteosarcoma

Bishop, M. W., Janeway, K. A., & Gorlick, R. G. (2015) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000298 · Cited by 266

Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs

Chen, C., Xie, L., Ren, T., Huang, Y., Xu, J. H., & Guo, W. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.12.024 · Cited by 582

Advances on immunotherapy for osteosarcoma

Yu, S., & Yao, X. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02105-9 · Cited by 270

Current and Emerging Targets in Immunotherapy for Osteosarcoma

Miwa, S., Shirai, T., Yamamoto, N., Hayashi, K., Takeuchi, A., Igarashi, K., & Tsuchiya, H. (2019) · Journal of Oncology · doi:10.1155/2019/7035045 · Cited by 123